Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

[1]  S. Abraham.  Lung-function trajectories leading to chronic obstructive pulmonary disease , 2015 .

[2]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[3]  Kayleigh Kew,et al.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[4]  F. Martinez,et al.  The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.

[5]  C. Jenkins,et al.  Cardiovascular events in patients with COPD: TORCH Study results , 2010, Thorax.

[6]  D. Postma,et al.  Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. , 2009, Annals of internal medicine.

[7]  W. MacNee,et al.  Vascular dysfunction in chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[8]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[9]  J. Vestbo,et al.  Increased T-regulatory cells within lymphocyte follicles in moderate COPD , 2009, European Respiratory Journal.

[10]  H. Magnussen,et al.  Physical activity in patients with COPD , 2008, European Respiratory Journal.

[11]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[12]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[13]  K. Rabe,et al.  Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.

[14]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[15]  Julie A. Anderson,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[16]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[17]  Milan C Mathew,et al.  The effects of a smoking cessation intervention on 14.5-year mortality. , 2005, Annals of internal medicine.

[18]  E. Salpeter,et al.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.

[19]  Don D. Sin,et al.  Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .

[20]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[21]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[22]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[23]  J. Pijoan,et al.  Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[24]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[25]  E. Metter,et al.  Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. , 1995, American journal of respiratory and critical care medicine.

[26]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[27]  C. Jenkins,et al.  Salmeterol/Fluticasone propionate and survival in chronic obstructive pulmonary disease:the TORCH trail. , 2007 .

[28]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[29]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[30]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.